Weekly Roundup (March 5-March 9, 2012): What We Read Crossing The ‘Bridge

This Week on the DataBridge

As usual, a week peppered with clinical research news was broken up by authoring some articles of our own.

To jumpstart the week, we discussed how experts are touting the promising future of medical devices. Then, in the middle of the week, we debated what’s in store for personalized cancer medicine, based on session reports from PMWC 2012.



Around the Web: Pharma R&D, Biosimilars Questions Headline the Clinical Research News of the Week

The flurry of news about clinical studies didn’t abate this week, so without further ado ...

Our CEO, Dr. Emma Banks, wrote an article for EPC about incorporating EDC technology into complex trials.

A Forbes editorial notes that there “has never really been” low-hanging fruit when it comes to pharma R&D, while another piece wonders “how much cheaper” biosimilars will really be. A new Greek law mandates that the industry “most cover pharma overspend,” and bonds “backed by drug-royalty cash flows” are bouncing back.

A USA Today article noted that drug makers have paid “$8 billion in fraud fines,” and another piece examined the idea of paying for prescription drugs “only if they work.” Some are wondering why CNS drugs “take 35% longer to develop” than others, while others report that the CNS pipeline is “second only to cancer” when it comes to number of drugs in development. An article shares the top 10 “VC medical device deals” of 2011, and one more documented the FDA weighing “expanding access” to medications.

An article examines why “new is not always better” when it comes to drugs.

In biotech news, small biotech firms are “raring to cash in” on the orphan disease market, and a protein complex “prods cells to crawl.” Pioneering research has revealed “bacterium’s secrets,” others have uncovered a “more effective method” of imaging proteins and still more have found a “foot in the door” to genetic information.

Elsewhere in biotech news developments, scientists are hard at work “unraveling biological networks,” and determining whether a genetic mutation will be problematic is as easy as “asking Spliceman.” Researchers are pursuing insights into how to turn on a “chemical switch” that increases stroke and heart disease risk, while an “embryonic development protein” is active in cancer growth.


Personalized Cancer Medicine Among the Hot Topics in Oncology Studies This Week

In oncology study news, researchers have discovered a “sarcoma tumor immune response” with combo therapy, while some feel that “leaving prostate cancer untreated” is best for some men. Cancer immunotherapy has a “new universal platform,” and researchers are looking into a potential new target to “counteract brain tumor resistance” to therapy.

Could a new machine “detect cancer by smell”?

An article looked into “improving the effectiveness” of chemotherapy, while another noted that combination therapy “may fight cancer better.” A new screening method could aid scientists in “identifying key information rapidly,” and a UK survey indicated that “thousands die early from cancer” due to ignorance and denial of symptoms. Researchers have found that a cancer drug “may stymie lung disease,” while “using patients’ own anti-tumor cells” could hold treatment promise for advanced melanoma.

Finally in developments in oncology studies, a new mechanism could explain “how tumor cells spread” to organs and structures and initiate metastasis, and a single biopsy can’t reveal a “tumor’s genetic identity.”


So what else did we miss when it comes to news about clinical studies this week? Did you see an article about the future of medical devices or have any personal experiences from PMWC 2012? How about any oncology study news that may have slipped past us?

Please feel free to share your links and observations in the comments section below, and remember to follow our Twitter stream and subscribe to our RSS feed to stay in the loop all week long. Thanks as always for reading the DataBridge, and have a great weekend!